Key Highlights

• electroCore fell more than 9% on June 24 with no negative regulatory or clinical development identified.

• The stock had gained approximately 69% year-to-date before the session's pullback.

• gammaCore Sapphire is approved for migraine prevention and cluster headache treatment.

• Broad small-cap healthcare selling drove the session rather than any company-specific catalyst.

electroCore (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company whose non-invasive vagus nerve stimulation device gammaCore Sapphire is approved for migraine prevention and cluster headache treatment, fell more than 9% on June 24 as broad selling in small-cap healthcare names created profit-taking pressure across the sector.

No negative regulatory or clinical development was identified for the session. The pullback follows a strong year-to-date run in which the stock had gained approximately 69%, a level of appreciation that makes any session of sector-wide risk aversion a natural trigger for position reduction among momentum-oriented investors.

electroCore's gammaCore Sapphire platform operates through non-invasive transcutaneous vagal nerve stimulation, delivering a differentiated mechanism of action that has received regulatory clearance across both migraine and cluster headache indications. The company has been expanding its commercial infrastructure to grow adoption among neurologists and headache specialists.

The June 24 decline does not reflect any adverse development in electroCore's regulatory position or commercial outlook, and the stock retains the operational progress that supported its year-to-date gains heading into the session.